Clinical Trials Logo

Clinical Trial Summary

Primary objective - To investigate the effectiveness of Jalosome® compared with placebo in the prevention and treatment of RID in patients with HNC undergoing RT. Secondary objectives: - To investigate the effectiveness of Jalosome® in reducing the maximum severity of RID compared with placebo. - To investigate the effect of Jalosome®, compared with placebo, on patients' quality of life. - To investigate safety and tolerability of Jalosome®. - To investigate patient's compliance to Jalosome® treatment. - To investigate patient's global satisfaction with Jalosome® treatment.


Clinical Trial Description

Primary endpoint: - Mean time difference in development of G2 RID (according to CTCA) between Jalosome® and placebo arms. A median difference of at least 7 days is considered of clinical significance. • Secondary endpoints: - Proportion of subjects without G2 RID at the end of RT, in the Jalosome® and placebo arms. - Proportion of subjects without G2 RID at different timepoints (week 5, week 6 and two weeks after the last radiation) in the Jalosome® and placebo arms. - Worst skin toxicity during treatment and up to 2 weeks after the last radiation, according to CTCAE, in the Jalosome® and placebo arms. - RID grade (mean and worst) on the RISRAS scale, assessed weekly, in the Jalosome® and placebo arms. - Mean and worst score of PRO-Skindex-16 questionnaire performed weekly, in the Jalosome® and placebo arms. - Mean pain measured by the 11-point NRS of the Brief Pain Inventory (BPI), as reported in patients' diary (daily) and assessed during visits (weekly), in the Jalosome® and placebo arms. - Patient's compliance to Jalosome® treatment. - Patient's global satisfaction with Jalosome® treatment. - Jalosome® overall safety and tolerability. Study design: Monocentric, randomized, double-blind, placebo controlled clinical trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05284487
Study type Interventional
Source Welcare Industries SpA
Contact Marco Gobbino
Phone +39 (0)763 316353
Email r&s@welcaremedical.com
Status Recruiting
Phase N/A
Start date March 27, 2023
Completion date March 2024

See also
  Status Clinical Trial Phase
Completed NCT01714973 - Study of ST266 Versus Saline in Treating Skin Irritation From Radiation Phase 1
Completed NCT02556632 - Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer Phase 2
Completed NCT02369835 - Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Phase 3
Completed NCT03374995 - Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer N/A
Not yet recruiting NCT05114226 - A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury Phase 1
Withdrawn NCT05073172 - StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients N/A
Completed NCT01246973 - Oral Curcumin for Radiation Dermatitis Phase 2/Phase 3